FindMyKOL
Clinical trialNCT04623944Active, not recruitingPhase 1Interventional

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

SponsorNkarta, Inc.Enrollment61AML, AdultMDSRefractory Myelodysplastic SyndromesRelapsed/Refractory AML
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Colorado Blood Cancer Institute

    Denver, Colorado, United States

  • Mayo Clinic Florida

    Jacksonville, Florida, United States

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia, United States

  • University of Chicago Medical Center

    Chicago, Illinois, United States

  • the Cleveland Clinic - Taussig Cancer Institute

    Cleveland, Ohio, United States

  • Sarah Cannon at Tristar Bone Marrow Transplant Center

    Nashville, Tennessee, United States

  • Md Anderson Cancer Center, University of Texas

    Houston, Texas, United States

  • Methodist Healthcare System of San Antonio

    San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

NKX101 - CAR NK cell therapy
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 Sept 2020
Primary completion
2 Oct 2024
Completion
31 Jul 2039
Last update posted
27 Dec 2024
Registered enrollment
61
Registry id
NCT04623944
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.